Our Team

We are a small team of talented professionals with a wide range of skills and experience. We love what we do, and we do it with passion. We look forward to working with you.

Awa Diagne

Chief Executive Officer

Awa Diagne is Computer Engineering graduate from Ecole Polytechnique de Montreal and Strategy from HEC-Paris. She has over 15 years of international experience in business process optimization and digital transformation in Life Sciences and Natural Resources industries. As Management Consultant, she has been supporting Fortune 500 companies such as Merck, Roche and Novartis. She is Senegalo-Canadian and has been living and working across the globe (Africa, America, Europe, Asia) for the last 20+ years. Through her expertise, she will be able to implement industry best practices in the operations of the business. In her free time, Awa practices meditations, volunteering and water sports.

Dr. Ahmed Haider

Director, Research and Development

Dr. Ahmed Haider studied pharmacology and obtained his PhD degree in Neuroimaging at the Swiss Federal Institute of Technology (ETH) in 2018. For his work on the early diagnosis of neurodegenerative disorders, such as Alzheimer’s Disease, Dr. Haider was awarded with the prestigious ETH Silver Medal and the Robert Eder Fonds Prize and has obtained 200’000 CHF of acquired project funding. He has collaborated with several pharmaceutical companies including Novartis, Roche, GE Healthcare and Takeda, thereby establishing a broad network within the pharmaceutical industry. After gaining insights into clinical studies at University Hospital Zurich for the past two years, Dr. Haider is currently moving his office to Boston (US), where he will be working at the Harvard Medical School and the Massachusetts General Hospital.

Dr. Hazem Farouk

Director, Clinical Development

Dr. Farouk is a pharmacist by training and a clinical researcher by experience. With in-depth knowledge within drug development, he obtained his PhD in Neuropharmacology and Radiopharmaceutical Sciences from the Swiss Federal Institutes of Technology, ETH Zurich. Focusing on patient-centred outcomes, Dr. Farouk is currently unravelling and tracing neurodegenerative diseases by positron emission tomography imaging while expediting the clinical translation of novel radiopharmaceuticals at the joint Centre of Radiopharmaceutical Sciences of ETH Zurich, University Hospital Zurich and Paul Scherrer Institute

Daniel Tay

Director, IT and Analytics

Daniel Tay completed his Bsc in Physics at the National University of Singapore, his Msc in Physical Sciences at the University of Chicago and is currently completing a PhD in Physics under Prof Gabriel Aeppli in the group of Prof Joel Mesot at ETH Zurich. His main research interest is in the use of Nuclear Magnetic Resonance (NMR) and Muon Spin Resonance (muSR) as local probes to image exotic electronic phenomena such as weyl semimetals, superconductivity and charge density waves. Daniel brings to the team his interdisciplinary scientific expertise and his data-driven approach to company finances. Daniel played goalkeeper in high school football and his favorite team is Liverpool.

Prof. Dr. Simon Ametamey

Advisory Board Member

Simon Mensah Ametamey is a senior scientist at the Institute for Pharmaceutical Sciences of ETH Zurich (Group Radiopharmaceutical Science) since April 2005. He earned his doctorate degree in Organic Chemistry from the University of Zurich under the guidance of with Prof. H.H. Heimgartner. Subsequently, he spent one year as a postdoctoral fellow with Prof. K. Bernhard at Hoffmann La Roche, Basel, Switzerland. In January 1995, Simon M. Ametamey became the group leader of the Radiotracer Synthesis research group at the Center for Radiopharmaceutical Science of ETH, PSI and USZ in Villigen. In 2001, he completed his habilitation in Radiopharmaceutical Chemistry at ETH Zurich, Switzerland. At present, Simon M. Ametamey is co-​head of the Animal Imaging Center-​PET. His research activities concentrate on the development of radiolabelled biomolecules for diagnostic application in brain diseases and tumor imaging. Currently, his research work concentrates on PET ligands for glutamatergic neurotransmission, gene therapy monitoring and folate receptors.